Understanding The Potential of NCL as A Drug Target and Biomarker

Target Name: NCL

NCBI ID: G4691

Content of Review Report on NCL Target / Biomarker

NCL

Other Name(s): NUCL_HUMAN | nucleolin | C23 | FLJ45706 | Nsr1 | Nucleolin | Protein C23

Understanding The Potential of NCL as A Drug Target and Biomarker

NCL (NUCL_HUMAN), a protein that belongs to the NCL family, has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its unique structure and biology make it an attractive target for researchers to study and develop new treatments.

The NCL family is a group of transmembrane proteins that are characterized by the presence of a nucleotide-binding oligomerization domain (NOD), which is responsible for the interaction with various nucleic acids. NCL proteins have been implicated in various physiological processes, including cell signaling, DNA replication, and stress responses.

One of the most promising aspects of NCL is its potential as a drug target is due to its unique structure and biology. NCL proteins have a distinct N-terminus that is rich in electrostatic and hydrophobic interactions, making them vulnerable to small molecules. Additionally, NCL proteins have a propensity to undergo conformational changes, which can alter their stability and interactivity with various components of the cell.

NCL has been shown to play a crucial role in various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. In cancer, NCL has been linked to the development and progression of various types of cancer, including breast, ovarian, and colorectal cancers. For example, studies have shown that high levels of NCL proteins are associated with poor prognosis in breast cancer patients.

In neurodegenerative diseases, NCL has been implicated in the development and progression of diseases such as Alzheimer's disease and Parkinson's disease. These conditions are characterized by the progressive loss of brain cells, which is thought to be caused by the build-up of toxic protein aggregates. NCL has been shown to be involved in the formation of these aggregates and may be a potential therapeutic target.

In autoimmune disorders, NCL has been linked to the development of conditions such as rheumatoid arthritis and multiple sclerosis. These conditions are characterized by the immune system attacking the body's own tissues, leading to inflammation and damage. NCL has been shown to play a role in the regulation of immune responses and may be a potential therapeutic target.

Despite the potential benefits of NCL as a drug target and biomarker, much research is still needed to fully understand its biology and develop new treatments. One of the major challenges in studying NCL is its complex structure, as the changes that occur at the N-terminus can make it difficult to study. Additionally, the lack of specific NCL inhibitors has made it difficult to determine the exact role of NCL in these diseases.

In conclusion, NCL is a protein that has the potential to be a drug target and biomarker for various diseases. Its unique structure and biology make it an attractive target for researchers to study and develop new treatments. Further research is needed to fully understand its role in these diseases and develop effective therapies.

Protein Name: Nucleolin

Functions: Nucleolin is the major nucleolar protein of growing eukaryotic cells. It is found associated with intranucleolar chromatin and pre-ribosomal particles. It induces chromatin decondensation by binding to histone H1. It is thought to play a role in pre-rRNA transcription and ribosome assembly. May play a role in the process of transcriptional elongation. Binds RNA oligonucleotides with 5'-UUAGGG-3' repeats more tightly than the telomeric single-stranded DNA 5'-TTAGGG-3' repeats

The "NCL Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about NCL comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets